{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chickenpox/background-information/complications/","result":{"pageContext":{"chapter":{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 0036b8e3-90de-4885-a7f4-6a4500406591 --><h2>What are the complications?</h2><!-- end field 0036b8e3-90de-4885-a7f4-6a4500406591 -->","summary":"","htmlStringContent":"<!-- begin item 8530de31-48a6-4fbc-a7ac-8f20753cc1ad --><!-- begin field 5c8294b5-606f-451e-b6d3-1c70d7e6583f --><ul><li>Adults, pregnant women, neonates, and immunocompromised people are more susceptible to serious complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>].</li></ul><!-- end field 5c8294b5-606f-451e-b6d3-1c70d7e6583f --><!-- end item 8530de31-48a6-4fbc-a7ac-8f20753cc1ad -->","topic":{"id":"5d1b7a44-f7ff-52e9-a218-c53ecadb0e4c","topicId":"4960f8a4-0140-4c3b-9bd0-b1ac6fccd648","topicName":"Chickenpox","slug":"chickenpox","lastRevised":"Last revised in August 2018","chapters":[{"id":"fe0450ab-ddfd-5960-bb47-b986d9cc6059","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff90f80f-13d4-5732-8d09-9c5566ce6ec2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes"},{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update"}]},{"id":"9d70228e-0283-5d34-a4af-5237097d0a02","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fa1d46ea-9d63-5d1a-b60c-9b96e87f802c","slug":"goals","fullItemName":"Goals"},{"id":"4e21e939-92fd-555c-a175-93b8a626169a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea18d1e8-0bdd-542f-a985-2952ecabca2d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d911096-5b50-551b-a17a-cff3070315b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"601f7c68-386e-5474-96f1-d6239bd81750","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"305e8fa8-8eb6-5b69-a902-93019e0c2c17","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"145f102c-4e0f-52c9-8b3b-e0b5c6eb112e","slug":"definition","fullItemName":"Definition"},{"id":"9f4d0cad-78a8-568f-831e-8878d2f4bfd3","slug":"transmission","fullItemName":"Transmission"},{"id":"5691920a-f618-5a98-ab32-417dfc782db1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications"}]},{"id":"a3eb8e9b-cdd9-5243-8353-09aac3fdc322","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff9f70a8-0c29-5357-946d-bbca67eafbbf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b651c5b4-34df-5480-b05d-909c9023a7a5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3844af91-e26b-515e-a645-9725d2f54810","fullItemName":"Management","slug":"management","subChapters":[{"id":"7700c175-994a-51d5-a2d0-36eb7478e2c1","slug":"child-or-adult","fullItemName":"Scenario: Child or adult"},{"id":"f6a62aa2-354d-5eee-a868-fb5d162115ef","slug":"pregnant-woman","fullItemName":"Scenario: Pregnant woman"},{"id":"c659257f-8875-5440-ae24-57c071cf226c","slug":"breastfeeding-woman","fullItemName":"Scenario: Breastfeeding woman"},{"id":"499e6045-af39-5bc4-952b-edcb6b29144f","slug":"neonate","fullItemName":"Scenario: Neonate"},{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised"},{"id":"072ae3a5-9cf4-5233-bca1-2d46e53de42b","slug":"exposure-to-chickenpox","fullItemName":"Scenario: Exposure to chickenpox"}]},{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir"}]},{"id":"95550d9e-6be2-5a94-924a-c4c2f8e7dbe4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"880099bb-bff8-543e-a1e8-267413ef45b9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c80905f1-b771-5170-8be8-c1bcee935552","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6bf66548-b486-53e1-bce7-d9bb45af9bea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"52168b40-dab0-5afb-9662-bb28014b5734","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5fa2da47-e83a-5886-9c1b-c6ae4e97a0a7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"769ea126-78ac-540c-a1c9-38446d44e22e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"87e1772a-0cd8-5e0c-ad7a-b676a65171bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"4d85d6a5-bd2e-526f-af1c-2b99f9722abc","slug":"children","fullItemName":"Children","depth":3,"htmlHeader":"<!-- begin field 9e50e08e-7847-4256-a1b3-f6e66270bcac --><h3>Complications in children</h3><!-- end field 9e50e08e-7847-4256-a1b3-f6e66270bcac -->","summary":null,"htmlStringContent":"<!-- begin item 4b5d035d-dd96-4ede-bdca-73a363415be9 --><!-- begin field 347e5be3-d6fd-4dcc-94ac-cae1dfd6a3b1 --><ul><li>Chickenpox is usually a self-limiting disease in healthy children, and complications are rare [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Lichenstein, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Papadopoulos, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Papadopoulos, 2007</a>]. However, complications may occur, including [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Lichenstein, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Gould, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Sturgeon et al, 2015</a>]:  <ul><li>Skin bacterial superinfection (for example impetigo, furuncles, cellulitis, erysipelas, necrotizing fasciitis) and scarring. This may manifest as sudden high grade pyrexia (often after initial improvement), erythema, and tenderness surrounding the original chickenpox lesions.</li><li>Neurological complications (for example Reye's syndrome, acute cerebellar ataxia, encephalitis, meningoencephalitis, polyradiculitis, myelitis).</li><li>In rare cases, myocarditis, glomerulonephritis, appendicitis, pancreatitis, Henoch–Schönlein purpura, orchitis, arthritis, optic neuritis, iritis, and keratitis.</li></ul></li></ul><!-- end field 347e5be3-d6fd-4dcc-94ac-cae1dfd6a3b1 --><!-- end item 4b5d035d-dd96-4ede-bdca-73a363415be9 -->","subChapters":[]},{"id":"7e078b6a-a6c7-53f6-8e9d-8f96f7fb8d22","slug":"adults","fullItemName":"Adults","depth":3,"htmlHeader":"<!-- begin field 92fda8b0-0ac0-4ead-9df6-b5ae65bca62e --><h3>Complications in adults</h3><!-- end field 92fda8b0-0ac0-4ead-9df6-b5ae65bca62e -->","summary":null,"htmlStringContent":"<!-- begin item 7ebaf941-581f-4989-91c4-eae8f761a9c5 --><!-- begin field a11a70eb-7ba2-468e-a323-3d37a5db124d --><ul><li>Chickenpox can be more serious in adults than in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>], and adults with varicella are more likely to be admitted to hospital [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Heininger and Seward, 2006</a>].</li><li>Complications include pneumonia, hepatitis, and encephalitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>].<ul><li>Smokers are particularly at risk of fulminating varicella pneumonia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li><li>Of the mortality related to chickenpox in England and Wales, 80% occurs in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>].</li></ul></li><li>Older age is a risk factor for severe varicella disease, and the risk of dying from varicella is highest at extremes of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Heininger and Seward, 2006</a>].</li><li>Shingles can occur from reactivation of latent varicella-zoster infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li></ul><!-- end field a11a70eb-7ba2-468e-a323-3d37a5db124d --><!-- end item 7ebaf941-581f-4989-91c4-eae8f761a9c5 -->","subChapters":[]},{"id":"b9b7038b-cd56-5054-b55b-9e24679fb1fb","slug":"pregnancy","fullItemName":"Pregnancy","depth":3,"htmlHeader":"<!-- begin field da47c19d-8563-4acb-bc5d-9df70eaa7023 --><h3>Complications in pregnancy</h3><!-- end field da47c19d-8563-4acb-bc5d-9df70eaa7023 -->","summary":null,"htmlStringContent":"<!-- begin item ed4d97fe-8c03-4c63-a7dc-dfeb07be8531 --><!-- begin field 08ca2d41-ab01-4873-82b7-3921a1cfe45f --><ul><li><strong>Complications for the mother:</strong><ul><li>Varicella in pregnancy can result in severe chickenpox. The mother is at increased risk of varicella pneumonia and other complications, compared with the general adult population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li><li>Around 1 in 10 pregnant women with chickenpox develop pneumonia; the severity increases with later gestation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>].</li><li>The case-fatality rate of pregnant women varies between case series, from 0–14% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>].</li></ul></li><li><strong>Complications for the fetus:</strong><ul><li>Infection with varicella-zoster during the first 28 weeks of pregnancy can lead to intrauterine infection and fetal varicella syndrome (previously known as congenital varicella syndrome), which is characterized by one or more of [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>]:<ul><li>Skin scarring in a dermatomal distribution.</li><li>Eye defects (for example microphthalmia, chorioretinitis, and cataracts).</li><li>Hypoplasia of the limbs.</li><li>Neurological abnormalities (microcephaly, cortical atrophy, learning difficulties, dysfunction of bowel and bladder sphincters).</li><li>The incidence of fetal varicella syndrome is less than 1% in the first 12 weeks, and around 2% between 13 and 20 weeks of pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>]. </li><li>Cases of fetal varicella syndrome have also been reported in women between 20 and 28 weeks of gestation, indicating that there is a small risk of fetal varicella syndrome when a woman develops chickenpox after 20 weeks of pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>]<strong>.</strong> The risk of fetal damage is likely to be lower than fetal varicella syndrome occurring in the first 20 weeks of pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li></ul></li></ul></li></ul><!-- end field 08ca2d41-ab01-4873-82b7-3921a1cfe45f --><!-- end item ed4d97fe-8c03-4c63-a7dc-dfeb07be8531 -->","subChapters":[]},{"id":"8d3f2f4b-b547-5b75-bb11-80a6e531e797","slug":"neonates","fullItemName":"Neonates","depth":3,"htmlHeader":"<!-- begin field 28910470-bdc3-4c31-b693-e85682222681 --><h3>Complications in neonates</h3><!-- end field 28910470-bdc3-4c31-b693-e85682222681 -->","summary":null,"htmlStringContent":"<!-- begin item f8394056-c85c-4a2f-a78a-1b4a7b0042ed --><!-- begin field 073853d7-a2f7-4022-a08e-41612c8af538 --><ul><li>Neonates are at increased risk of disseminated or haemorrhagic varicella [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li><li>If the mother becomes infected 1–4 weeks before delivery, up to half of babies will be infected; and around a quarter will develop clinical varicella of the newborn, even though they have passively acquired maternal antibody. If the baby is born up to 7 days before or 7 days after onset of the mother's rash, it is more likely to develop severe infection, which may be fatal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>].</li><li>If maternal infection occurs at 20–27 weeks of pregnancy, the baby may develop shingles of infancy or early childhood due to reactivation of the primary in-utero infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">HPA, 2011</a>].</li></ul><!-- end field 073853d7-a2f7-4022-a08e-41612c8af538 --><!-- end item f8394056-c85c-4a2f-a78a-1b4a7b0042ed -->","subChapters":[]},{"id":"8dd7afa1-86bd-53ad-a446-e4f04a1b74ef","slug":"immunocompromised-people","fullItemName":"Immunocompromised people","depth":3,"htmlHeader":"<!-- begin field b1b73240-7617-422d-aff0-da967052adac --><h3>Complications in immunocompromised people</h3><!-- end field b1b73240-7617-422d-aff0-da967052adac -->","summary":null,"htmlStringContent":"<!-- begin item 2971f751-100f-41e2-a9be-9197b5c3d809 --><!-- begin field 1432c78e-546a-4f02-a10e-0de587d2629a --><ul><li>Severe disseminated chickenpox with haemorrhagic complications is more common in immunocompromised people than in other population groups [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li><li>Immunocompromised people with chickenpox are also at increased risk of pneumonia, encephalitis, disseminated intravascular coagulopathy, and hepatitis<strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">CDC, 2016</a>].</li></ul><!-- end field 1432c78e-546a-4f02-a10e-0de587d2629a --><!-- end item 2971f751-100f-41e2-a9be-9197b5c3d809 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}